Vandana Singh AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis ...

Vijay Singh will be the next CEO of Vermont Public. Courtesy Vijay Singh After a 10-month nationwide search, the public media organization’s board settled on Singh as its next leader.

The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, the company has said, months after the pharmaceutical firm ...

With healthcare investors crowded into the obesity-focused drugmakers, AstraZeneca, a leader in cancer at a more reasonable ...

Manish Singh is a senior reporter at TechCrunch, covering India’s startup scene and venture capital investments. He also reports on global tech firms’ India play. Before joining TechCrunch in ...

"It's appalling the way AstraZeneca has been treated. I wouldn't blame them if they were thoroughly fed up and decided to bow out of the Covid vaccine business." That was the view from one of the ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

Tampa, Fla.-based Moffitt Cancer Center and drugmaker AstraZeneca are collaborating to accelerate the development of CAR-T cell and T cell receptor therapies. "We are excited to collaborate with ...